RxDoctor Payments Data

Thomas Pickron, MD

Colon & Rectal Surgery · Salt Lake City, UTNPI 1598733941

Payments from drug & device makers

What this record shows

This record is dominated by education: $35,593 of the $55,261 with a category attached, or 64.4%. Intuitive Surgical accounts for 92.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $19,401 and has fallen 78.9% since, to $4,085 in 2025.

$55,261in general payments, 2019–2025

Across 100 payments — averaging $552.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$51K
  • Applied Medical Resources Corporation$4K
  • AbbVie$127
  • Johnson & Johnson$82
$251,544in research payments, 2019–2025

Across 59 payments — averaging $4263.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$252K

What the payments were for

  • Speaking & faculty fees$5,50010%
  • Travel & lodging$10,61219%
  • Food & beverage$3,5566%
  • Education$35,59364%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$79,324
Medicare patients
142
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin Sulfate40$204
Metronidazole41$57
Ondansetron OdtOndansetron29$47

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →